1-(chloromethyl)-2,4-diethylbenzene | 187979-66-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(chloromethyl)-2,4-diethylbenzene
• CAS: 187979-66-4
• 化学式: C₁₁H₁₅Cl
• 分子量: 182.693
• InChiKey: PCVCGHKIFLAPDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS
  申请人：Glick Gary D.

  公开号：US20090118244A1

  公开（公告）日：2009-05-07

  The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.

  本发明提供了一类苯二氮卓酮化合物及其药物组合物。本发明还提供了治疗某些皮肤病症的方法，例如特应性皮炎、酒渣鼻或银屑病，通过给予苯二氮卓酮以及通过将角质细胞暴露于苯二氮卓酮来减少角质细胞增殖的方法。
• [EN] BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME<br/>[FR] COMPOSÉS DE BENZODIAZÉPINONE ET MÉTHODES DE TRAITEMENT LES UTILISANT
  申请人：UNIV MICHIGAN

  公开号：WO2011035124A1

  公开（公告）日：2011-03-24

  The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.

  该发明提供了1,4-苯并二氮杂酮化合物、药物组合物以及治疗自身免疫性疾病、慢性炎症性疾病和过度增殖性疾病的方法。例如，这些1,4-苯并二氮杂酮化合物和药物组合物被认为对治疗类风湿关节炎、移植物抗宿主病、炎症性肠病等疾病有用。
• BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME
  申请人：Glick Gary D.

  公开号：US20120232067A1

  公开（公告）日：2012-09-13

  The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.

  本发明提供了1,4-苯二氮卓酮类化合物、制药组合物以及治疗自身免疫性疾病、慢性炎症性疾病和过度增生性疾病的方法。例如，考虑到1,4-苯二氮卓酮类化合物和制药组合物可用于治疗类风湿性关节炎、移植物抗宿主病、炎症性肠病等疾病。
• Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0268878A2

  公开（公告）日：1988-06-01

  Disclosed herein are salicylic acid copolymers having a weight average molecular weight of 500 10,000 and obtained (a) by condensing salicylic acid (i) with a benzyl alcohol (ii) and/or benzyl ether (iii) or a benzyl halide (iv) in the presence of an acid catalyst or (b) by reacting a co-condensation resin of (i) and (ii) and/or (iii) with (iv) or (c) by reacting a co-condensation resin of (i) and (ii) and/or (iii) or (iv) with a styrene derivative in the presence of an acid catalyst; multivalent metal salts of the salicylic acid copolymers; color-developing agents comprising the multivalent metal salts; and color-developing sheets suited for pressure-sensitive copying paper and comprising the color-developing agents. Their production processes are also disclosed.

  本文公开了水杨酸共聚物，其重量平均分子量为 500 10、000 的水杨酸共聚物；(a)在酸催化剂存在下，将水杨酸(i)与苄醇(ii)和/或苄醚(iii)或苄基卤化物(iv)缩合而得，或(b)将(i)和(ii)和/或(iii)的共缩合树脂与(iv)反应而得，或(c)在酸催化剂存在下，将(i)和(ii)和/或(iii)或(iv)的共缩合树脂与苯乙烯衍生物反应而得；水杨酸共聚物的多价金属盐；由多价金属盐组成的显色剂；以及由显色剂组成的适用于压敏复印纸的显色薄片。此外，还公开了它们的生产工艺。
• Color-developing compositions and their use
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0523697A1

  公开（公告）日：1993-01-20

  A color-developing composition comprises a multivalent-metal-modified salicylic acid resin (Resin A) and a polycondensation resin (resin B) at a weight ratio of 90-30 to 10-70. Resin A is composed of 5-35 mole% of a structural unit (I) and 65-95 mole% of at least one structural unit (II) or 65-95 mole% of a coupled structural unit of at least one unit (II) and at least one unit (III) and has a weight-average molecular weight of 350-5,000. Resin B is composed of the unit (II) and/or the unit (III) and has a weight-average molecular weight of 350-5,000. wherein Z represents M/m, M being a metal ion of m valence and m being an integer; R₁ and R₂ represent H or a C₁₋₁₂ alkyl, aralkyl, aryl or cycloalkyl group; R₃ and R₆ represent H or a C₁₋₄ alkyl group; and R₄ and R₅ represent H or CH₃.

  一种显色组合物包括一种多价金属改性水杨酸树脂（树脂 A）和一种缩聚树脂（树脂 B），两者的重量比为 90-30 比 10-70。树脂 A 由 5-35 摩尔%的结构单元（I）和 65-95 摩尔%的至少一个结构单元（II）或 65-95 摩尔%的至少一个单元（II）和至少一个单元（III）的耦合结构单元组成，其重量平均分子量为 350-5000。树脂 B 由单元（II）和/或单元（III）组成，重量平均分子量为 350-5000。 其中 Z 代表 M/m，M 为 m 价金属离子，m 为整数；R₁ 和 R₂ 代表 H 或 C₁₋₁₂ 烷基、芳基、芳烷基或环烷基；R₃ 和 R₆ 代表 H 或 C₁₋₄ 烷基；以及 R₄ 和 R₅ 代表 H 或 CH₃。